An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Mise à jour : Il y a 4 ans
Référence : NCT01397305

Femme et Homme

  • | Pays :
  • Sweden
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to determine whether an optimal dose of [6R] 5,10-methylenetetrahydrofolate (Modufolin) in combination with pemetrexed are effective in pre-operative treatment of patients with resectable rectal cancer.


Critère d'inclusion

  • Rectal cancer

Liens